Edition:
India

LivaNova PLC (LIVN.OQ)

LIVN.OQ on NASDAQ Stock Exchange Global Select Market

85.78USD
2:29am IST
Change (% chg)

$1.40 (+1.66%)
Prev Close
$84.38
Open
$84.99
Day's High
$85.84
Day's Low
$84.81
Volume
173,788
Avg. Vol
144,963
52-wk High
$85.84
52-wk Low
$42.98

Latest Key Developments (Source: Significant Developments)

LivaNova says breaching co to pay $6 mln if deal with Microport collapses
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Microport Scientific Corp <0853.HK>:LivaNova - If deal to sell co's cardiac rhythm management business to Microport Cardiac Rhythm terminated‍, breaching party to pay termination fee of $6 million.  Full Article

Microport Scientific's unit buys CRM business from Livanova
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Microport Scientific Corp <0853.HK>::Announces ‍acquisition of CRM business from Livanova PLC​.‍Unit buys CRM business for initial consideration of US$190 million​ from Livanova PLC.  Full Article

LivaNova Plc reports ‍Q3 diluted earnings per share were $0.57​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - LivaNova Plc :LivaNova Plc - ‍Q3 2017 diluted earnings per share were $0.57​.LivaNova Plc - ‍Q3 2017 adjusted diluted earnings per share were $0.93​.LivaNova Plc - ‍Reiterates that worldwide net sales for full-year 2017 will remain between 1 and 3 percent growth on a constant currency basis​.LivaNova Plc - ‍Adjusted diluted earnings per share projections for full-year 2017 are now expected to be in range of $3.30 to $3.45​.LivaNova Plc - Qtrly ‍net sales $309.7 million versus $295.3 million​.Q3 earnings per share view $0.78, revenue view $300.5 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.25 -- Thomson Reuters I/B/E/S.  Full Article

Livanova receives FDA approval for Vagus Nerve Stimulation Therapy system​
Monday, 9 Oct 2017 

Oct 9 (Reuters) - Livanova Plc ::Livanova receives FDA approvals for SenTiva device and next-generation VNS therapy programming system for treatment of epilepsy.Says received U.S. FDA approvals for Vagus Nerve Stimulation Therapy system​.  Full Article

LivaNova Q2 adjusted earnings per share $0.87
Wednesday, 3 Aug 2016 

LivaNova Plc : LivaNova reports second quarter 2016 results . Q2 sales $321 million . Q2 adjusted earnings per share $0.87 . Q2 gaap earnings per share $0.18 .Company reiterates its guidance for full year 2016.  Full Article

Livanova says approved a share repurchase program of up to $150 million
Tuesday, 2 Aug 2016 

: Says approved the authorization of a share repurchase program of up to $150 million . Livanova PLC says program authorizes co to repurchase up to $30 million of shares from September 1, 2016 through December 31, 2016 - SEC Filing Source - http://bit.ly/2aPthJz Further company coverage: [LIVN.L] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Livanova Plc says to reorganises unit; cuts 140 jobs in France - Reuters News
Thursday, 10 Mar 2016 

Livanova Plc:Livanova Plc reorganisation plan for Cardiac Rhythm Management business unit.Plan also contemplates closure of company's research and development facility in Meylan, France.Estimates that these actions will result in total pre-tax charges of approximately $16 million to $21 million in 2016.Reorganisation plan will result in a reduction of around 140 in workforce, primarily based at company's facility in Clamart, France.Plan contemplates consolidation of business unit's research and development capabilities into clamart facility.  Full Article

LivaNova PLC gives FY 2016 guidance
Wednesday, 24 Feb 2016 

LivaNova PLC:Expects FY 2016 worldwide sales growth of between 3% and 5% over 2015.Expects FY 2016 adjusted non-GAAP diluted EPS to be in the range of $2.95 to $3.15.Expects FY 2016 adjusted non-GAAP EBITDA to be in the range of $235 million to $260 million.  Full Article

LivaNova PLC provides update on FDA warning letter
Tuesday, 5 Jan 2016 

LivaNova PLC:Provides update on FDA warning letter.Says currently believes that less than 1 percent of 2016 consolidated sales could be impacted by warning letter.Says further meetings are planned with FDA in order to clarify certain aspects of the warning letter.Says had got a warning letter FDA alleging certain violations of regulations at its Munich, Germany and arvada, Colorado facilities.  Full Article

BRIEF-Microport Scientific's unit buys CRM business from Livanova

* ‍Unit buys CRM business for initial consideration of US$190 million​ from Livanova PLC Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

No consensus analysis data available.